Last reviewed 2026-05-20 · How we verify

Enterocura (SULFAGUANOLE)

Phase 2 active Small molecule ✓ Verified May 2026

Enterocura (generic name: SULFAGUANOLE) is a sulfaguanole drug. It is currently in Phase 2 development.

Enterocura works by inhibiting bacterial enzymes, disrupting the bacteria's ability to carry out essential functions.

Enterocura is a small molecule medication. It is also known by the synonyms Sulfaguanol and Sulfaguanole.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULFAGUANOLE
Drug class	sulfaguanole
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of it like a key that fits into a lock. The bacteria have special locks that help them make proteins and grow. Enterocura is like a key that blocks these locks, preventing the bacteria from making the proteins they need to survive and multiply.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Enterocura CI brief — competitive landscape report
Enterocura updates RSS · CI watch RSS

Frequently asked questions about Enterocura

What is Enterocura?

Enterocura (SULFAGUANOLE) is a sulfaguanole drug.

How does Enterocura work?

Enterocura works by inhibiting bacterial enzymes, disrupting the bacteria's ability to carry out essential functions.

What is the generic name of Enterocura?

SULFAGUANOLE is the generic (nonproprietary) name of Enterocura.

What drug class is Enterocura in?

Enterocura belongs to the sulfaguanole class. See all sulfaguanole drugs at /class/sulfaguanole.

What development phase is Enterocura in?

Enterocura is in Phase 2.

Drug class: All sulfaguanole drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing